Immunotherapy for transplantation-associated viral infections

被引：50

作者：

Roddie, Claire ^{[1
,2
]}

Peggs, Karl S. ^{[1
,2
]}

机构：

[1] UCL, Canc Inst, Dept Haematol, Paul OGorman Bldg,72 Huntley St, London WC1E 6DD, England

[2] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2017年 / 127卷 / 07期

基金：

英国医学研究理事会;

关键词：

STEM-CELL TRANSPLANTATION; EPSTEIN-BARR-VIRUS; CYTOTOXIC T-LYMPHOCYTES; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE; PREVENT CYTOMEGALOVIRUS DISEASE; SOLID-ORGAN TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; HLA-PEPTIDE TETRAMERS; ADOPTIVE IMMUNOTHERAPY;

D O I：

10.1172/JCI90599

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections following allogeneic hematopoietic stem cell transplantation (HSCT) are a major cause of morbidity and mortality. Early clinical trials demonstrate that adoptive transfer of donor-derived virus-specific T cells to restore virus-specific immunity is an effective strategy to control CMV and EBV infection after HSCT, conferring protection in 70%-90% of patients. The field has evolved rapidly to develop solutions to some of the manufacturing challenges identified in early clinical studies, such as prolonged in vitro culture, optimization of the purity of the virus-specific T cell product, the potential limitations of targeting a single viral antigen, and how to manage the patient with a virus-naive donor. This Review both discusses the seminal early studies and explores cutting-edge novel technologies that broaden the feasibility of and the scope for delivering virus-specific T cells to patients after HSCT.

引用

收藏

页码：2513 / 2522

页数：10

相关论文

共 93 条

[81] USE OF GENE-MODIFIED VIRUS-SPECIFIC T-LYMPHOCYTES TO CONTROL EPSTEIN-BARR-VIRUS-RELATED LYMPHOPROLIFERATION [J].

ROONEY, CM ;

SMITH, CA ;

NG, CYC ;

LOFTIN, S ;

LI, CF ;

KRANCE, RA ;

BRENNER, MK ;

HESLOP, HE .

LANCET, 1995, 345 (8941) :9-13

[82] Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation [J].

Schmitt, Anita ;

Tonn, Torsten ;

Busch, Dirk H. ;

Grigoleit, Goetz Ulrich ;

Einsele, Hermann ;

Odendahl, Marcus ;

Germeroth, Lothar ;

Ringhoffer, Mark ;

Ringhoffer, Simone ;

Wiesneth, Markus ;

Greiner, Jochen ;

Michel, Detlef ;

Mertens, Thomas ;

Rojewski, Markus ;

Marx, Martin ;

von Harsdorf, Stephanie ;

Doehner, Hartmut ;

Seifried, Erhard ;

Bunjes, Donald ;

Schmitt, Michael .

TRANSFUSION, 2011, 51 (03) :591-599

[83] CMV-Specific TCR-Transgenic T Cells for Immunotherapy [J].

Schub, Andrea ;

Schuster, Ingrid G. ;

Hammerschmidt, Wolfgang ;

Moosmann, Andreas .

JOURNAL OF IMMUNOLOGY, 2009, 183 (10) :6819-6830

[84] Therapeutic strategies for the prevention and treatment of cytomegalovirus infection [J].

Sellar, Rob S. ;

Peggs, Karl S. .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (09) :1161-1172

[85] Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus [J].

Sester, M ;

Sester, U ;

Gärtner, B ;

Kubuschok, B ;

Girndt, M ;

Meyerhans, A ;

Köhler, H .

JOURNAL OF VIROLOGY, 2002, 76 (08) :3748-3755

[86] Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines [J].

Styczynski, Jan ;

van der Velden, Walter ;

Fox, Christopher P. ;

Engelhard, Dan ;

de la Camara, Rafael ;

Cordonnier, Catherine ;

Ljungman, Per .

HAEMATOLOGICA, 2016, 101 (07) :803-811

[87] Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects [J].

Sylwester, AW ;

Mitchell, BL ;

Edgar, JB ;

Taormina, C ;

Pelte, C ;

Ruchti, F ;

Sleath, PR ;

Grabstein, KH ;

Hosken, NA ;

Kern, F ;

Nelson, JA ;

Picker, LJ .

JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (05) :673-685

[88] Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective [J].

Tomblyn, Marcie ;

Chiller, Tom ;

Einsele, Hermann ;

Gress, Ronald ;

Sepkowitz, Kent ;

Storek, Jan ;

Wingard, John R. ;

Young, Jo-Anne H. ;

Boeckh, Michael A. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (10) :1143-1238

[89] Rapid Salvage Treatment With Virus-Specific T Cells for Therapy-Resistant Disease [J].

Uhlin, Michael ;

Gertow, Jens ;

Uzunel, Mehmet ;

Okas, Mantas ;

Berglund, Sofia ;

Watz, Emma ;

Brune, Mats ;

Ljungman, Per ;

Maeurer, Mark ;

Mattsson, Jonas .

CLINICAL INFECTIOUS DISEASES, 2012, 55 (08) :1064-1073

[90] Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease [J].

Vickers, Mark A. ;

Wilkie, Gwen M. ;

Robinson, Nicolas ;

Rivera, Nadja ;

Haque, Tanzina ;

Crawford, Dorothy H. ;

Barry, Jacqueline ;

Fraser, Neil ;

Turner, David M. ;

Robertson, Victoria ;

Dyer, Phil ;

Flanagan, Peter ;

Newlands, Helen R. ;

Campbell, John ;

Turner, Marc L. .

BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (03) :402-410

← 1 2 3 4 5 6 7 8 9 10 →